RVP · Retractable Technologies Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $38.27M | $33.05M | $43.60M | $94.82M | $188.38M | $81.86M |
| Cost of Revenue | $38.22M | $34.08M | $34.49M | $66.57M | $93.03M | $44.85M |
| Gross Profit | $47.0K | ($1.03M) | $9.11M | $28.25M | $95.35M | $37.01M |
| R&D | $675.6K | $673.9K | $581.2K | $525.7K | $901.4K | $574.5K |
| SG&A | $12.77M | $13.56M | $14.31M | $24.04M | $17.38M | $8.30M |
| Total Operating Expenses | $21.22M | $20.08M | $20.60M | $29.11M | $22.76M | $12.94M |
| D&A | $7.77M | $7.57M | $7.53M | $4.60M | $1.26M | $832.1K |
| Operating Income | ($21.18M) | ($21.11M) | ($11.49M) | ($853.0K) | $72.60M | $24.07M |
| Interest Expense | $87.9K | $122.5K | $152.2K | $170.7K | $227.2K | $260.3K |
| Income Tax | $291.3K | $8.37M | ($1.91M) | $83.9K | $18.89M | $1.85M |
| Net Income | ($12.57M) | ($11.89M) | ($7.01M) | $5.08M | $56.06M | $24.22M |
| EPS - Basic | ($0.43) | ($0.40) | ($0.24) | $0.15 | $1.65 | $0.80 |
| EPS - Diluted | ($0.43) | ($0.40) | ($0.24) | $0.15 | $1.63 | $0.80 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.59M | $4.24M | $12.67M | $19.72M | $29.16M | $17.57M |
| Accounts Receivable | $7.90M | $7.79M | $10.67M | $4.84M | $34.86M | $32.91M |
| Inventory | $17.19M | $19.19M | $17.58M | $20.68M | $20.59M | $10.23M |
| Accounts Payable | $5.34M | $4.29M | $4.78M | $6.40M | $20.40M | $16.26M |
| Current Assets | $63.08M | $73.27M | $77.65M | $88.81M | $104.51M | $69.48M |
| Total Assets | $142.63M | $160.72M | $179.67M | $195.67M | $206.30M | $104.97M |
| Current Liabilities | $9.60M | $8.78M | $9.38M | $12.14M | $35.32M | $27.90M |
| Long-term Debt | $895.6K | $900.0K | $1.23M | $1.53M | $1.81M | $2.71M |
| Total Liabilities | $68.26M | $73.55M | $80.38M | $89.13M | $107.14M | $55.09M |
| Stockholders' Equity | $74.38M | $87.17M | $99.29M | $106.54M | $99.17M | $49.88M |
| Retained Earnings | $13.87M | $26.67M | $38.79M | $46.03M | $41.18M | ($9.67M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($7.06M) | ($11.56M) | $2.77M | $16.77M | $32.79M | $19.00M |
| Investing Cash Flow | $5.98M | $3.66M | ($10.76M) | ($31.20M) | ($63.04M) | ($19.33M) |
| Financing Cash Flow | ($567.3K) | ($535.4K) | $941.6K | $4.99M | $41.84M | $11.96M |
| CapEx | - | $1.44M | $853.0K | $16.83M | $58.37M | $21.05M |
| Free Cash Flow | - | ($13.00M) | $1.91M | ($61.9K) | ($25.57M) | ($2.05M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 0.1% | -3.1% | 20.9% | 29.8% | 50.6% | 45.2% |
| Operating margin | -55.3% | -63.9% | -26.4% | -0.9% | 38.5% | 29.4% |
| EBITDA margin | -35.0% | -41.0% | -9.1% | 4.0% | 39.2% | 30.4% |
| Net margin | -32.8% | -36.0% | -16.1% | 5.4% | 29.8% | 29.6% |
| Free cash flow margin | - | -39.3% | 4.4% | -0.1% | -13.6% | -2.5% |
| FCF / Net income | - | 1.09 | -0.27 | -0.01 | -0.46 | -0.08 |
| R&D / Revenue | 1.8% | 2.0% | 1.3% | 0.6% | 0.5% | 0.7% |
| SG&A / Revenue | 33.4% | 41.0% | 32.8% | 25.3% | 9.2% | 10.1% |
| Effective tax rate | - | - | - | 1.6% | 25.2% | 7.1% |
| Return on assets | -8.8% | -7.4% | -3.9% | 2.6% | 27.2% | 23.1% |
| Return on equity | -16.9% | -13.6% | -7.1% | 4.8% | 56.5% | 48.6% |
| Return on invested capital | -22.2% | -18.9% | -9.0% | -0.8% | 53.8% | 42.5% |
| Liquidity | ||||||
| Current ratio | 6.57 | 8.34 | 8.28 | 7.32 | 2.96 | 2.49 |
| Quick ratio | 4.78 | 6.16 | 6.41 | 5.61 | 2.38 | 2.12 |
| Cash ratio | 0.27 | 0.48 | 1.35 | 1.63 | 0.83 | 0.63 |
| Leverage | ||||||
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.05 |
| Debt / Assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 |
| Debt / EBITDA | - | - | - | 0.41 | 0.02 | 0.11 |
| Interest coverage | -240.9x | -172.3x | -75.5x | -5.0x | 319.5x | 92.5x |
| Equity multiplier | 1.92 | 1.84 | 1.81 | 1.84 | 2.08 | 2.10 |
| Liabilities / Assets | 0.48 | 0.46 | 0.45 | 0.46 | 0.52 | 0.52 |
| Efficiency | ||||||
| Asset turnover | 0.27 | 0.21 | 0.24 | 0.48 | 0.91 | 0.78 |
| Inventory turnover | 2.22 | 1.78 | 1.96 | 3.22 | 4.52 | 4.38 |
| Days sales outstanding | 75d | 86d | 89d | 19d | 68d | 147d |
| Days inventory outstanding | 164d | 206d | 186d | 113d | 81d | 83d |
| Days payable outstanding | 51d | 46d | 51d | 35d | 80d | 132d |
| Cash conversion cycle | 189d | 246d | 225d | 97d | 68d | 98d |
| Valuation | ||||||
| P / E | - | - | - | 10.9x | 4.3x | 13.4x |
| P / B | 0.3x | 0.2x | 0.3x | 0.5x | 2.4x | 7.2x |
| P / S | 0.6x | 0.6x | 0.8x | 0.6x | 1.3x | 4.4x |
| EV / EBITDA | - | - | - | 9.6x | 2.8x | 13.8x |
| Growth | ||||||
| Revenue growth (YoY) | 15.8% | -24.2% | -54.0% | -49.7% | 130.1% | 95.9% |
| Revenue CAGR (3y) | -26.1% | -44.0% | -18.9% | 31.4% | 84.8% | 33.4% |
| Revenue CAGR (5y) | -14.1% | -4.6% | 7.9% | 22.4% | 44.6% | 22.6% |
| Gross profit growth (YoY) | - | - | -67.8% | -70.4% | 157.7% | 161.8% |
| Operating income growth (YoY) | -0.3% | -83.7% | -1246.8% | - | 201.6% | 710.0% |
| Net income growth (YoY) | -5.7% | -69.5% | - | -90.9% | 131.5% | 669.4% |
| EPS growth (YoY) | -7.5% | -66.7% | - | -90.8% | 103.7% | 1042.9% |
| EPS CAGR (3y) | - | - | - | 28.9% | - | - |
| EPS CAGR (5y) | - | - | - | - | - | 32.0% |
| FCF growth (YoY) | - | - | - | 99.8% | -1145.9% | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -14.7% | -12.2% | -6.8% | 7.4% | 98.8% | 74.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$32.24M totalSingle Reportable Segment$32.24M · 100.0%
Product / service
$32.24M totalSyringes$21.08M · 65.4%
Easy Point Needles$9.78M · 30.3%
Blood Collection Products$1.34M · 4.2%
Other Products$30.9K · 0.1%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
0.62
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing RETRACTABLE TECHNOLOGIES INC against the 5 most active filers in the same SIC group.